Combining BET inhibitors and PARP inhibitors might help patients resistant to chemotherapy, the study suggests.

Scientists at St. John’s University, The University of Pennsylvania and Université de Montréal have identified poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the ...

Cancer Discovery publishes high-impact articles featuring major advances in research and clinical trials. Topics span the spectrum of cancer research and medicine from the laboratory to the clinic to ...

Patients taking PARP inhibitors should have regular lab tests of red blood cell, white blood cell, and platelet counts. If side effects occur, dotors can consider adjusting dosage or temporarily ...

PARP inhibitors are a type of targeted cancer treatment commonly used to treat cancers caused by faults in the BRCA1 and BRCA2 genes. They work by stopping PARP from repairing damage in cancer cells, ...

UPMC Hillman Cancer Center, University of Pittsburgh, 5115 Centre Ave, Pittsburgh, Pennsylvania 15232, United States Department of Computational and Systems Biology, University of Pittsburgh, 3420 ...

This month's cover highlights the article Nup358 restricts ER-mitochondria connectivity by modulating mTORC2/Akt/GSK3β signalling by Joseph, Misha Kalarikkal and colleagues. The image shows a human ...

FIGURE 2. The effect of palbociclib on ABCB1 ATPase activity in the absence or presence of the ABCB1 ATPase inhibitor, tepotinib. The black line represents the basal ABCB1 ATPase activity after ...

Immunotherapy uses our immune system to fight cancer. Targeted treatments include cancer growth blockers, drugs that block cancer blood vessel growth and PARP inhibitors. Immunotherapy treatments ...

According to recent market analysis, the global PARP inhibitor market, valued at USD 6,279.90 million in 2024, is set to witness exceptional growth, reaching USD 16,153.50 million by 2034. This ...